Abstract: Increasing rates of multi-drug resistant (MDR) and extremely-drug resistant (XDR) cases of tuberculosis (TB) strains are alarming, which eventually hampered an effective control of the pathogenic disease. In present study, 9 derivatives of 2,3-bis(2-oxochromen-3-yl)-1,4-diphenyl-butane-1,4-dione (11a-c) and 3,4-(dicoumarin-3-yl)-2,5-diphenyl furans and pyrroles (12a-f) have been synthesized successfully. The experimental data for the Anti-tuberculosis activity (using MABA assay) of 2,3-bis(2-oxochromen-3-yl)-1,4-diphenyl-butane-1,4-dione (11a-c) revealed that in this series compound 11a showed better minimum inhibitory concentration of 1.6 mg/ml against Mycobacterium tuberculosis (H37 RV strain) ATCC No- 27294 which was better than the MIC value of Pyrazinamide-3.125 mg/ml, Streptomycin-6.25 mg/ml and Ciprofloxacin- 3.125 mg/ml. Our synthesis and in-vitro studies thus pointed out the moderate to good anti-TB profiles of substituted furans and pyrroles.